April 13, 2026 — LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients showed a 40% disease control rate and encouraging survival trends with an acceptable safety profile, supporting continued enrollment of an expanded cohort as the company investigates the combination’s potential to enhance immunotherapy response in ovarian clear cell carcinoma.
April 13, 2026 — As supply deficits continue to influence platinum markets, the precious metal has registered a 30% climb in its price so far this year. This is according to a report on commodity prices published in April by the World Bank.
April 13, 2026 — Stanford University scientists developed a molecular urine analysis that can distinguish bladder cancer patients who need immunotherapy from those already cured by surgical removal, transforming treatment planning for roughly 60,000 Americans diagnosed yearly with early-stage disease. As many more companies like Calidi Biotherapeutics Inc.
April 13, 2026 — The rise of artificial intelligence has sparked fear and uncertainty about the future of work, especially for people just starting their careers. Many believed that entry-level jobs would disappear as machines took over basic tasks.
April 13, 2026 — American Fusion (OTC: AMFN) a developer of next-generation fusion energy technologies, reported its participation in the 2026 ARPA-E Energy Innovation Summit, where the company advanced its commercialization strategy, strengthened relationships with government agencies, research institutions and industry participants, and refined its positioning within the evolving fusion landscape. The company highlighted progress on its Texatron(TM) roadmap, identified data centers as a key initial customer segment for high-density power solutions, evaluated supply chain partnerships for critical inputs such as helium-3 and deuterium, and explored potential capital markets expansion, including a Frankfurt listing, as it moves toward scalable deployment of its modular fusion technologies.
April 13, 2026 — Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising.
April 13, 2026 — This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.
April 13, 2026 — This article has been disseminated on behalf of Nicola Mining Inc. and may include paid advertising.
April 13, 2026 — Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company focused on brain-targeted therapeutics, announced that the first patient has been dosed in its Phase IIa clinical trial evaluating ONP-002 for concussion and mild traumatic brain injury at Mackay Hospital in Australia, shortly after site activation on March 31, 2026. The milestone follows regulatory approval and highlights progress in advancing a first-in-class intranasal neurosteroid designed to address underlying brain injury mechanisms, as the company expands trial sites and targets a large unmet need in a condition with no FDA-approved pharmacological treatments.
April 13, 2026 — Safe Pro Group (NASDAQ: SPAI), a developer of AI-enabled defense, security and situational awareness solutions, announced the commercial rollout of its NODE-X, a next-generation, miniaturized AI-powered edge compute processor designed to analyze drone footage for real-time threat detection in military missions, following a recent government contract award. The backpack-deployable system leverages the company’s patented SPOTD technology trained on millions of real-world images to detect threats such as landmines, UXO and drones, while generating 3D mapping and route guidance without connectivity, and is scheduled for additional U.
April 13, 2026 — NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD and related conditions, announced the appointment of Glenn Tyson as its first Chief Commercial Officer as the company prepares for anticipated approval of its Abbreviated New Drug Application for a preservative-free ketamine product. Tyson brings more than 25 years of commercialization and sales experience, including senior leadership roles at GSK and Indivior, where he led the successful launch of SUBLOCADE(R), and will oversee the buildout of market access, distribution, sales and marketing capabilities to support upcoming product launches and the company’s broader psychiatry pipeline, including NRX-100 and NRX-101.
April 13, 2026 — This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.
April 13, 2026 — The global train collision avoidance system market is expected to reach $13. 32 billion by 2030, growing at a compound annual growth rate (“CAGR”) of an estimated 15%.
April 10, 2026 — On a cold Friday afternoon near the New York–Pennsylvania border, cars begin to line up outside Organic Blooms, a recreational cannabis shop that has quickly become a regional draw. Vehicles with New York plates share space with those from Pennsylvania, a sign of a growing cross-border market fueled by differing state laws.
April 10, 2026 — This article has been disseminated on behalf of Xanadu Quantum Technologies Limited and may include paid advertising. Xanadu Quantum Technologies (NASDAQ, TSX: XNDU) shares jumped more than 20% in active trading, climbing to $9.
April 10, 2026 — Olenox Industries (NASDAQ: OLOX) announced it has amended its letter of intent with Vivakor Inc. (OTC: VIVKD) to acquire the Omega pipeline system and related midstream assets, extending the expected closing date to April 30, 2026, as the companies continue diligence and audit processes.
April 10, 2026 — DitGold (CRYPTO: DITAU) announced the implementation of a Companion Contract Architecture designed to strengthen security and scalability without altering its core token or disrupting existing liquidity. The model integrates a TokenTimelock.
April 10, 2026 — Frontieras is developing breakthrough technologies that convert abundant solid hydrocarbons such as coal into cleaner fuels, hydrogen and industrial energy products. Central to this strategy is the company’s patented FASForm(TM) Solid Carbon Fractionation process.
April 10, 2026 — Future Money Acquisition (NASDAQ: FMACU) announced the closing of its initial public offering of 11,200,000 units priced at $10. 00 per unit, generating gross proceeds of approximately $112 million, including the partial exercise of the underwriters’ over-allotment option.
April 10, 2026 — Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF)and may include paid advertising.
